Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Photoreceptors and Visual Pathways

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Role of autologous platelet-rich plasma for recurrent or refractory macular hole in the era of various flap techniques: a meta-analysis.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026

Same author

Preoperative Parameters Associated with Vitrectomy Outcomes in Myopic Traction Maculopathy Without a Full-Thickness Macular Hole.

Life (Basel, Switzerland)·2026

Same author

Efficacy of Tumor Necrosis Factor-α Inhibitor Adalimumab in Chronic Recurrent Vogt-Koyanagi-Harada Disease.

Pharmaceuticals (Basel, Switzerland)·2025

Same author

Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes.

Journal of clinical medicine·2025

Same author

Diagnostic Performance of Universal Transport Medium for Viral Polymerase Chain Reaction in Aqueous Humor Samples of Suspected Viral Uveitis: A Pilot Methods Study.

International journal of molecular sciences·2025

Same author

Reinjection in Patients with Intraocular Inflammation Development after Intravitreal Brolucizumab Injection.

Korean journal of ophthalmology : KJO·2025

Search research articles

Related Experiment Video

Updated: Mar 31, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Retinal Detachment and Proliferative Vitreoretinopathy.

Oh Woong Kwon, Ji Hun Song, Mi In Roh

Developments in Ophthalmology

|October 27, 2015

Summary

Proliferative vitreoretinopathy (PVR) remains a leading cause of retinal detachment (RD) repair failure. Research is exploring pharmacologic therapies to inhibit cellular proliferation and contraction, aiming to improve surgical outcomes for RD and PVR.

Area of Science:

Ophthalmology
Retinal Surgery
Vitreoretinal Diseases

Background:

Retinal detachment (RD) affects approximately 5 per 100,000 people annually.
Proliferative vitreoretinopathy (PVR) complicates 5.1–11.7% of primary RD cases and is the main cause of surgical failure.
Recurrent vitreoretinal traction leads to redetachment in over 25% of initially successful RD repairs.

Purpose of the Study:

To review current surgical management strategies for RD and PVR.
To highlight the role of retinal pigment epithelial cells, soluble mediators, and extracellular matrix in PVR development.
To explore emerging adjuvant pharmacologic therapies for inhibiting PVR.

Main Methods:

Review of current surgical techniques including pneumatic retinopexy, scleral buckling, and pars plana vitrectomy (PPV).

More Related Videos

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Published on: January 25, 2019

Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate

Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate

Published on: September 11, 2013

Related Experiment Videos

Last Updated: Mar 31, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Published on: January 25, 2019

Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate

Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate

Published on: September 11, 2013

Analysis of the pathophysiology of PVR, focusing on cellular proliferation and extracellular matrix involvement.

Examination of recent studies on pharmacologic agents targeting PVR development.

Main Results:

Surgical success rates for PVR have improved with advancements in vitrectomy techniques.
Despite improvements, recurrent vitreoretinal traction remains a significant challenge, causing redetachment.
Retinal pigment epithelial cells are central to PVR initiation, with mediators and ECM playing key roles.

Conclusions:

Pars plana vitrectomy (PPV) is crucial for RD and PVR treatment, but adjuvant therapies are needed to prevent recurrence.
Pharmacologic agents like daunorubicin, 5-fluorouracil, and heparin are being investigated to inhibit PVR.
Further research into PVR pathophysiology is essential for developing effective prophylactic and adjunctive treatments.